FDA: Abbott failed to reveal facts about Prism

Share this article:
The FDA says product information sheets, a launch presentation and a customer letter for Abbott’s Prism HBsAg (antibody to hepatitis B surface antigen [mouse monoclonal IgM]) and Prism HBcore (hepatitis B virus core antigen [E. coli, [recombinant]) were false and misleading because they failed to reveal facts on important risks associated with the products.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.